Compare Ascendis Pharma A/S (ASND) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Invesco NASDAQ 100 ETF — how do they compare? Ascendis Pharma A/S trades at $263.88 (market cap $17.74B), while Invesco NASDAQ 100 ETF trades at $295.06. Which is the better fit depends on your goals.
| ASND | QQQM | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $277.18 | $307.23 |
52-Week Low | $163.32 | $228.02 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
QQQM trades at $298.71, up 0.32% with a bullish technical signal from moving averages. The ETF benefits from Nasdaq 100 exposure, particularly growth-oriented tech stocks, with recent news highlighting SpaceX's inclusion in the index. Support levels are firm at $295 and $293, while resistance sits near $299 and $301.
The outlook remains positive given the ETF's focus on AI-driven growth companies and strong institutional interest. Risks include market volatility and concentration in tech, but long-term growth prospects from sectors like AI infrastructure support a favorable view for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
